Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate
March 27, 2025
-
BUSINESS J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
-
BUSINESS FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
March 25, 2025
-
COMMENTARY Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
-
BUSINESS New BMS Japan Chief Vows Bold Resource Allocation towards Doubling of Sales
March 21, 2025
-
BUSINESS Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
-
REGULATORY US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
-
BUSINESS Novartis CEO Touts Plan to Amp Up Japan Investment, Add 50 Jobs for Early Trials
March 18, 2025
-
BUSINESS Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
-
BUSINESS KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug
March 14, 2025
-
REGULATORY MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
-
REGULATORY Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
-
BUSINESS More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll
March 12, 2025
-
BUSINESS Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey
March 11, 2025
-
BUSINESS Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
March 11, 2025
-
BUSINESS Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
-
REGULATORY Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
March 10, 2025
-
REGULATORY MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
-
REGULATORY Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
-
ORGANIZATION Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…